Results from the phase III TROPiCS-02 study showed that sacituzumab govitecan improved OS compared with physician’s choice of single-agent chemotherapy in patients with previously treated HR+/HER2- advanced breast cancer.Results from the phase III TROPiCS-02 study showed that sacituzumab govitecan improved OS compared with physician’s choice of single-agent chemotherapy in patients with previously treated HR+/HER2- advanced breast cancer.